Skip to content
DataLookout
Menu

NCT07585071

IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Start date: Jun 15, 2026 to Dec 15, 2026
    • Eligibility criteria expanded, about 41 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence and severity of adverse events
Timeframe: Up to 3 months after IASO206 infusion

Secondary (1)

Proportion of patients achieving response

Arms and interventions

IASO206Experimental

Subjects will receive a single infusion of IASO206 injection in a 3+3 dose-escalation design. Three ascending dose cohorts are planned: 1E8 TU, 3E8 TU, and 5E8 TU. In each dose cohort, the first subject will be observed for at least 3 weeks after infusion before subsequent subjects in the same cohort receive IASO206 injection.

Biologicals: IASO206 injection